On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

420 with CNW – Poll Shows Americans want CBD as an OTC Drug

A survey conducted by Gallup has found that the majority of Americans who are familiar with CBD (cannabidiol) want it available as an over-the-counter drug. The results of the survey were released on Friday last week (June 14).

The CBD craze traces its roots to the cannabis reform movement, and it gained momentum when the Farm Bill 2018 became law last year. This bill legalized industrial hemp and all its derivatives, including CBD.

The survey involving 1,017 participants was conducted over the phone in a bid to get insights into the widespread appeal of CBD. The interviews were conducted from May 15-30.

In all, 39 percent of the people polled revealed that they want to see CBD available as an OTC drug while 21 percent said CBD should be accessed using a doctor’s prescription. 36 percent of the people polled revealed that they weren’t familiar with this particular compound of hemp and marijuana plants.

When Gallup focused on those who were familiar with CBD and asked them whether CBD should be purchased as an OTC drug or as a prescription drug, 61 percent favored the OTC option while 33 percent preferred to see it as a prescription drug.

The participants in the poll were also asked to rate how familiar they were with CBD. 14 percent looked at themselves as “very familiar” with it, 33 percent felt they were “somewhat familiar”, 17 percent felt they were “not too familiar” while 36 percent confessed that they “weren’t familiar at all” with cannabidiol.

Gallup again narrowed its attention to only those who categorized themselves as very familiar with cannabidiol and asked them for their opinion about the medicinal value of CBD. 90 percent of this group believed that CBD had therapeutic benefits.

Of those who thought CBD had medicinal benefits, 33 percent said it had “a lot of benefits”, 45 percent felt CBD had “some benefits” and 14 percent thought cannabidiol had “a few benefits.” 3 percent were neutral on the matter while 4 percent said cannabidiol didn’t have any medical benefits.

Commenting about their findings, Gallup wrote that most Americans already believe that CBD has medicinal value even if research has been slow in proving or disproving many of the therapeutic benefits attributed to CBD. Gallup is convinced that the fraction of people who think CBD is medicinal is most likely to grow as more people get exposed to this non-psychoactive compound.

This possibility takes on a greater degree of certainty given that the FDA has already been convinced enough of CBD’s therapeutic benefits to the extent of approving a drug targeting rare forms of epilepsy.

The pressure on federal agencies like the FDA and Congress to pass laws legalizing CBD as a food supplement and other uses is therefore going to increase as the months go by.

Cannabis industry analysts are of the opinion that the Gallup findings didn’t catch industry players like Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) and Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) by surprise.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office


Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 303.498.7722